NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category (Ascending) | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
17856-0759-06 | 17856-0759 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 14, 2021 | In Use | |
17856-0759-07 | 17856-0759 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 12, 2023 | In Use | |
17856-0759-08 | 17856-0759 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 14, 2021 | In Use | |
23155-0875-03 | 23155-0875 | Letrozole Tablets | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | June 1, 2023 | In Use | ||
23155-0875-09 | 23155-0875 | Letrozole Tablets | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | June 1, 2023 | In Use | ||
23155-0875-10 | 23155-0875 | Letrozole Tablets | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | June 1, 2023 | In Use | ||
00430-0720-24 | 00430-0720 | Estradiol | ESTRACE | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | Dec. 26, 2011 | Aug. 31, 2025 | In Use | |
00430-0721-24 | 00430-0721 | Estradiol | ESTRACE | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Dec. 26, 2011 | Aug. 31, 2025 | In Use | |
00430-0722-24 | 00430-0722 | Estradiol | ESTRACE | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Dec. 26, 2011 | Aug. 31, 2025 | In Use | |
16729-0436-30 | 16729-0436 | Fulvestrant | FULVESTRANT | 250.0 mg/5mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Jan. 21, 2021 | In Use |
Found 10,000 results in 8 milliseconds — Export these results